2024年1至12月份，荣旗科技的营业收入构成为：高端装备制造占比100.0%。 每经AI快讯，荣旗科技（SZ 301360，收盘价：72.73元）发布公告称，2025年11月11日至11月21日期 间，荣旗科技接受博时基金等投资者调研，公司董事、副总经理、财务总监兼董事会秘书王桂杰女士， 实际控制人、董事、副总经理朱文兵先生参与接待，并回答了投资者提出的问题。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 曾健辉） 截至发稿，荣旗科技市值为39亿元。 ...

Group 1 - The company, Puris (SZ 301257), announced that it will conduct investor research from October 31, 2025, to November 21, 2025, with the participation of the board secretary, Lai Xiaolong [1] - As of the latest report, Puris has a market capitalization of 3.4 billion yuan [2] - For the first half of 2025, Puris reported that its revenue composition is entirely from the service industry, accounting for 100% [1]

11月18日，继南网能源（003035）、南网科技、南网储能（600995）后，南方电网培育的第4家上市企 业——南方电网数字电网研究院股份有限公司在深圳证券交易所正式挂牌上市。这是南方电网加快融入 资本市场的又一重大突破，也标志着南方电网全面数字化智能化转型进入了新的发展阶段。 战略引领，锚定科产融合发展航向 孟振平表示，南方电网公司将深入贯彻落实数字中国、能源强国战略部署，进一步做强做优做大数字电 网产业生态，更好服务支撑能源电力产业智能化、绿色化、融合化转型升级，加快塑造能源电力生产力 新质态。接下来，将全力支持南网数字高质量发展，将其打造成为数字电网领域的龙头上市公司，以优 秀业绩回报广大投资者和社会各界。 "十四五"以来，南网数字充分发挥央企科技创新、产业引领、安全支撑作用，以"云-管-边-端-芯"贯通 协同的核心技术和能力，打造全场景、全环节产品体系，构建电网数字化、企业数字化和数字基础设施 三大业务体系，为电力客户提供安全、高效的数字化建设整体解决方案，并凭借深厚的技术积累和实践 经验，逐步拓展交通、水务燃气、政务公安、智慧城市等领域。 科技赋能，铸就数字电网硬核成果 在关键核心技术攻关方面，南 ...

智通财经APP讯，凯格精机(301338.SZ)公告，公司收到总经理邓迪先生送达的广东省东莞市第一人民法 院对其作出的《刑事判决书》，邓迪先生因犯危险驾驶罪，被判处拘役一个月，缓刑三个月，并处罚金 人民币3500元。 ...

Core Viewpoint - Anqihome (600298.SH) plans to increase its registered capital and implement a production line expansion project in Russia, aiming for an annual production capacity of 22,000 tons of yeast, with an investment amount of 1.062 billion yuan [1] Group 1 - The investment is part of the company's strategy to accelerate its global production layout and build a regional supply chain [1] - This move is expected to enhance the company's overall competitiveness in the global yeast market [1]

证券之星消息，11月21日期货概念板块较上一交易日下跌3.56%，中金岭南领跌。当日上证指数报收于 3834.89，下跌2.45%。深证成指报收于12538.07，下跌3.41%。期货概念板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603319 | 美湖股份 | 36.49 | 1.50% | 19.79万 | 7.14亿 | | 601236 | 红塔证券 | 8.47 | -2.08% | 18.86万 | 1.60亿 | | 600755 | 厦门国贸 | 6.55 | -2.24% | 79.57万 | 5.27亿 | | 600208 | 衢州发展 | 3.91 | -2.98% | 1 73.71万 | 2.92亿 | | 603093 | 草不朗器 | 18.29 | -3.07% | 4.52万 | 8356.87万 | | 601878 | 浙商证券 | 10.91 | -3.19% | 48.36万 | 5.34亿 | | 600704 | 物产中大 ...

每经AI快讯，步长制药（SH 603858，收盘价：16.74元）11月21日晚间发布公告称，截至本公告披露 日，公司及控股子公司已提供的担保总额为人民币约22.16亿元，占2024年末经审计的公司净资产的 21.69%。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 2024年1至12月份，步长制药的营业收入构成为：医药行业占比99.71%，其他业务占比0.29%。 截至发稿，步长制药市值为177亿元。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 ...

Core Insights - Fosun Pharma's subsidiary has received acceptance for a drug registration application for Luvofatin (复迈宁) to treat pediatric patients with Langerhans Cell Histiocytosis (LCH) aged 2 and above, which is now included in the priority review process by the National Medical Products Administration (NMPA) [1] - The drug is already approved in China for two indications: treating LCH in adults and symptomatic, inoperable plexiform neurofibromas in children and adolescents with Neurofibromatosis Type 1 (NF1) [1] - The drug is currently in Phase III clinical trials for treating adult NF1 and low-grade gliomas in children, and in Phase II trials for treating extra-cranial arteriovenous malformations [1] - The drug has been included in the breakthrough therapy program for adult patients with inoperable or residual/recurrent NF1-related plexiform neurofibromas by the NMPA [1] Financial Insights - As of October 2025, the cumulative R&D investment for the drug is approximately RMB 638 million (unaudited) [2] - According to IQVIA MIDAS data, the global sales for MEK1/2 selective inhibitors are projected to be around USD 2.068 billion in 2024 [2]

Group 1 - Sichuan Road and Bridge announced a share buyback of approximately 7.65 million shares, accounting for 0.0879% of the total share capital, with a total expenditure of about 70.2 million RMB [1][1][1] - The highest and lowest prices for the repurchased shares were 9.85 RMB and 8.62 RMB per share, respectively [1][1][1] - As of the report date, the market capitalization of Sichuan Road and Bridge is 79.9 billion RMB [1][1][1] Group 2 - For the year 2024, the revenue composition of Sichuan Road and Bridge is as follows: logistics trade 6.25%, mining and new materials 3.12%, highway investment and operation 2.69%, other businesses 0.6%, and clean energy 0.57% [1][1][1]

Core Insights - Anqihome (600298.SH) announced plans to increase registered capital and implement a production line expansion project for yeast, aiming for an annual output of 22,000 tons [1] - The investment amount for this project is 1.062 billion yuan [1] - This investment is a strategic move to accelerate the company's global production layout and build a regional supply chain, enhancing its overall competitiveness in the global yeast market [1]